Alpha-fetoprotein-associated alterations of New Zealand mouse immunopathology

M. Eric Gershwin, James J. Castles, Ronald Makishima

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The influence(s) of chronic injections of alpha-fetoprotein (AFP), derived from murine amniotic fluid, on the natural history of immunopathology and autoantibody production in New Zealand mice was studied and compared to analagous treatment with albumin, transferrin, or phosphate-buffered saline. Treatment of young New Zealand Black (NZB) mice with AFP, at sera levels of 60-210 μg/ml, significantly reduces the titer of IgG1, IgG2, and IgA antierythrocyte antibodies. Similarly, such treated mice have relatively normal levels of splenic Thy-1.2-bearing cells and sera immunoglobulins, at older ages, compared to control groups. In contrast, AFP has no apparent effect on the appearance of either naturally occurring thymocytotoxic antibodies (NTA) or lymphoma. Moreover, these positive features of AFP on disease were only noted for mice treated early in life; AFP had no effect when injected into older animals. Similar, but not as dramatic, changes were observed in NZB × NZW F1 hybrids. It is concluded that in pharmacologic doses, mouse amniotic fluid enriched with AFP may alter the appearance of thymic-dependent autoantibodies.

Original languageEnglish (US)
Pages (from-to)331-341
Number of pages11
Issue number4
StatePublished - 1979


  • Alpha-fetoprotein
  • Autoimmunity
  • New Zealand Mice

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Alpha-fetoprotein-associated alterations of New Zealand mouse immunopathology'. Together they form a unique fingerprint.

Cite this